Precision for Medicine GmbH
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Epiontis GmbH (to 2021)
2
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 6 to 20, 2026 · next Dec 6
- 1 fee due Feb 15, 2027The maintenance fee for Epigenetic Method for the Identification of Follicular T-Helper-(TFH-) Cells (US 11,725,243) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
- 2 fees due Mar 12 to 19, 2027 · next Mar 12
- 1 fee due Apr 17, 2027The maintenance fee for MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells (US 11,788,141) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Sep 17, 2027The maintenance fee for Detection of immune cells, in particular T cells through DNA-methylation analysis of the genes CCR6 and BLR1 (US 10,590,475) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for ERGIC1 as Epigenetic Marker for the Identification of Immune Cells, in Particular Monocytic Myeloid-Derived Suppressor Cells (mMDSCs) (US 11,976,327) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 22, 2026
- Sep 8 US 12,729,403 MYH11/NDE1 Region as Epigenetic Marker for the Identification of Endothelial Progenitor Cells (EPCS)
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,876,163 | Detection and quality control of regulatory T cells through DNA-methylation analysis of the Foxp3 gene In force · High confidence | In force | High confidence | |
| US 12,286,675 | Epigenetic markers for the identification of blood sub-cells of type 1 In force · USPTO record | In force | USPTO record | |
| US 10,590,475 | Detection of immune cells, in particular T cells through DNA-methylation analysis of the genes CCR6 and BLR1 In force · USPTO record | In force | USPTO record | |
| US 10,273,545 | Epigenetic Method for the Identification of Subpopulations of CD8+ T Lymphocytes, in Particular CD8 Alpha and Beta T Lymphocytes In force · High confidence | In force | High confidence | |
| US 10,781,492 | Epigenetic method for the identification of subpopulations of CD8+ T lymphocytes, in particular CD8 alpha and beta T lymphocytes In force · USPTO record | In force | USPTO record | |
| US 10,208,346 | Method for identifying the quantitative cellular composition in a biological sample In force · USPTO record | In force | USPTO record | |
| US 10,894,984 | Method for identifying the quantitative cellular composition in a biological sample In force · USPTO record | In force | USPTO record | |
| US 11,643,687 | LRP5 as Epigenetic Marker for the Identification of Immune Cells, in Particular B-Cells In force · High confidence | In force | High confidence | |
| US 11,761,041 | PARK2 as epigenetic marker for the identification of immune cells, in particular monocytes In force · USPTO record | In force | USPTO record | |
| US 11,788,141 | MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 no status recorded